Forbes • Sept 14 2016
By Jeffrey Lieberman
Departing from the massive complex of buildings that house the Food and Drug Administration after a meeting with the new FDA Commissioner, Robert Califf, I felt something that I rarely have felt on prior encounters with heads of major government agencies: elation. It was clear from the three-hour-plus discussion that Commissioner Califf held with key mental health stakeholder organizations that this newly installed bureaucrat (in the good sense of the term) clearly understood drug development and had the administrative and political savvy to tackle the formidable task of leading this all-important (when it comes to healthcare and therapeutics development) component of the federal government and manage its sprawling scope of responsibilities.
Recent Comments